ABSTRACT

Introduction

Candida species have been regarded as global health threats due to their ability to cause invasive infections. It is challenging to treat Candida bloodstream infections, which are associated with high mortality levels. Monotherapy with antifungals is sometimes not effective against severe Candida infections, and combination therapy is needed in clinical practice.

Areas covered

This review was undertaken based on data from a PubMed search for English language reports published before March 2021 by using the terms ‘caspofungin,’ ‘Candida species,’ ‘combination therapy,’ ‘antifungal effect,’ and ‘novel antifungal agent.’

Expert opinion

Combination therapy is an empirical strategy for treating refractory Candida infections. Caspofungin has been recommended to treat candidaemia. Caspofungin in combination therapy has some applications, while the efficacy of combination therapy in the treatment of refractory Candida infections needs more study, such as randomized controlled trials. In addition, novel compounds or drugs with potential antifungal activities have been examined, and some of them exhibit synergistic interactions with caspofungin. Thus, the antifungal activity of caspofungin in combination with antifungals or non-antifungals against Candida species in vitro and in clinical therapy is summarized.

中文翻译：

---

卡泊芬净联合抗真菌药或非抗真菌药对念珠菌属的体外和临床治疗的抗真菌活性

摘要

介绍

念珠菌由于能够引起侵袭性感染而被视为全球健康威胁。治疗与高死亡率相关的念珠菌血流感染具有挑战性。抗真菌药单药治疗有时对严重的念珠菌感染无效，临床实践中需要联合治疗。

涵盖的领域

这项审查是根据 PubMed 搜索 2021 年 3 月之前发布的英语报告的数据进行的，使用的术语是“卡泊芬净”、“念珠菌属”、“联合疗法”、“抗真菌作用”和“新型抗真菌剂”。

专家意见

联合疗法是治疗难治性念珠菌感染的经验策略。卡泊芬净已被推荐用于治疗念珠菌血症。卡泊芬净在联合治疗中有一定的应用，而联合治疗在治疗难治性念珠菌感染方面的疗效需要更多的研究，如随机对照试验。此外，已经研究了具有潜在抗真菌活性的新型化合物或药物，其中一些表现出与卡泊芬净的协同相互作用。因此，总结了卡泊芬净联合抗真菌剂或非抗真菌剂在体外和临床治疗中对念珠菌属的抗真菌活性。